Latest Capital Raises News

Peak Processing reported its first positive EBITDA month in March 2026, driven by operational efficiencies and strong production growth. The company upgraded its Q4 production forecast and expanded key customer contracts, signaling a turning point after a challenging period.

Southern Palladium reported a doubling in chromite recoveries at its Bengwenyama project, prompting a redesign of the processing plant and pushing the DFS completion to late Q4 2026 amid drilling delays and enhanced metallurgical work.

Rokeby Resources bolsters its portfolio with the acquisition of the high-grade Omeo Gold Project in Victoria, while unveiling promising exploration results at its Queensland assets and planning a delayed drilling campaign. The company has secured $4 million in capital commitments and announced key leadership changes.

Cosmos Exploration is advancing its Bolivian lithium ambitions by exercising its option to acquire 100% of EAU Lithium and raising A$5 million to fund exploration and acquisition costs.

HyTerra Ltd is progressing its flagship Nemaha hydrogen project with a key production test planned for Q2 2026, while expanding its global footprint through strategic partnerships and a $7 million capital raise.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.

Omega Oil and Gas has secured a commanding acreage position in Queensland’s Taroom Trough and fully funded an expanded drilling program to accelerate appraisal and early production.

Sky Metals has bolstered its cash reserves with a $20.5 million raise, backing a major drilling push at Tallebung and expanding exploration at Doradilla, positioning both projects for significant resource growth and development progress.

Syrah Resources delivered a record 24kt graphite production at Balama and secured US$72 million in equity to support medium-term ramp-up and Vidalia commercialisation, navigating a complex US trade environment.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

Prospect Resources has delivered further gold assay results from its Nyungu Central deposit, reinforcing the potential for valuable by-product credits at the Mumbezhi Copper Project and setting the stage for an aggressive Phase 3 drilling campaign.

TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.